DE602004022266D1 - Lkarzinoms der blase - Google Patents
Lkarzinoms der blaseInfo
- Publication number
- DE602004022266D1 DE602004022266D1 DE602004022266T DE602004022266T DE602004022266D1 DE 602004022266 D1 DE602004022266 D1 DE 602004022266D1 DE 602004022266 T DE602004022266 T DE 602004022266T DE 602004022266 T DE602004022266 T DE 602004022266T DE 602004022266 D1 DE602004022266 D1 DE 602004022266D1
- Authority
- DE
- Germany
- Prior art keywords
- cancer
- individual
- expression
- develop
- lkarzinoms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 201000011510 cancer Diseases 0.000 abstract 3
- 230000000694 effects Effects 0.000 abstract 3
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 abstract 1
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 abstract 1
- 206010005084 bladder transitional cell carcinoma Diseases 0.000 abstract 1
- 201000001528 bladder urothelial carcinoma Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 229940126601 medicinal product Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200300708 | 2003-03-26 | ||
| PCT/EP2004/003219 WO2004085676A1 (en) | 2003-03-26 | 2004-03-25 | In vitro method to detect bladder transitional cell carcinoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE602004022266D1 true DE602004022266D1 (de) | 2009-09-10 |
Family
ID=33041266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE602004022266T Expired - Lifetime DE602004022266D1 (de) | 2003-03-26 | 2004-03-25 | Lkarzinoms der blase |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8124331B2 (de) |
| EP (1) | EP1611252B1 (de) |
| AT (1) | ATE437963T1 (de) |
| DE (1) | DE602004022266D1 (de) |
| DK (1) | DK1611252T3 (de) |
| ES (1) | ES2330634T3 (de) |
| WO (1) | WO2004085676A1 (de) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| US9089601B2 (en) | 2006-07-10 | 2015-07-28 | University Of Rochester | Pre- and intra-operative imaging of bladder cancer |
| ES2323927B1 (es) * | 2007-03-30 | 2010-05-14 | Laboratorios Salvat, S.A. | Metodo in vitro no invasivo para detectar carcinoma transicional de vejiga. |
| EP2313435A4 (de) * | 2008-07-01 | 2012-08-08 | Aveo Pharmaceuticals Inc | An den fibroblastenwachstumsfaktorrezeptor 3 (fgfr3) bindende proteine |
| CN104788564A (zh) * | 2009-03-25 | 2015-07-22 | 健泰科生物技术公司 | 抗-fgfr3抗体及其使用方法 |
| WO2014018841A1 (en) * | 2012-07-27 | 2014-01-30 | Genentech, Inc. | Methods of treating fgfr3 related conditions |
| TWI606066B (zh) * | 2012-09-27 | 2017-11-21 | 中外製藥股份有限公司 | FGFR3 Fusion Gene and Its Targeted Medicine |
| WO2018027091A1 (en) | 2016-08-05 | 2018-02-08 | The Research Foundation For The State University Of New York | Keratin 17 as a biomarker for bladder cancer |
| US11505611B2 (en) | 2020-08-21 | 2022-11-22 | Genzyme Corporation | FGFR3 antibodies and methods of use |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030087854A1 (en) * | 2001-09-10 | 2003-05-08 | Isis Pharmaceuticals Inc. | Antisense modulation of fibroblast growth factor receptor 3 expression |
| EP1208231B2 (de) | 1999-05-05 | 2009-12-30 | Institut Curie | Mittel zum nachweis und zur behandlung von krankheiten die in verbindung stehen mit fgfr3 |
| ATE440869T1 (de) | 2001-06-20 | 2009-09-15 | Fibron Ltd | Fgfr3 blockierende antikírper, verfahren zum screening darauf und verwendungen davon |
-
2004
- 2004-03-25 EP EP04723215A patent/EP1611252B1/de not_active Expired - Lifetime
- 2004-03-25 WO PCT/EP2004/003219 patent/WO2004085676A1/en active Application Filing
- 2004-03-25 ES ES04723215T patent/ES2330634T3/es not_active Expired - Lifetime
- 2004-03-25 AT AT04723215T patent/ATE437963T1/de not_active IP Right Cessation
- 2004-03-25 US US10/550,608 patent/US8124331B2/en active Active
- 2004-03-25 DK DK04723215T patent/DK1611252T3/da active
- 2004-03-25 DE DE602004022266T patent/DE602004022266D1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DK1611252T3 (da) | 2009-11-23 |
| EP1611252A1 (de) | 2006-01-04 |
| US20070092878A1 (en) | 2007-04-26 |
| ES2330634T3 (es) | 2009-12-14 |
| ATE437963T1 (de) | 2009-08-15 |
| US8124331B2 (en) | 2012-02-28 |
| WO2004085676A1 (en) | 2004-10-07 |
| EP1611252B1 (de) | 2009-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR060306A1 (es) | Terapia de combinacion de anticuerpos contra ctla4 | |
| BR0308290A (pt) | Tratamento e prevenção de distúrbios inflamatórios | |
| ATE547420T1 (de) | Azepinoindol und pyridoindolderivate als pharmazeutische mittel | |
| LTPA2017009I1 (lt) | Brutono tirozinkinazės inhibitoriai | |
| AR047841A1 (es) | Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios | |
| BR112015025711A8 (pt) | uso de ibrutinibe e coposição farmacêutica compreendendo ibrutinibe e um agente anticâncer | |
| NO20044462L (no) | Anvendelse av EP4-reseptorligander i behandling av IL-6 involverte sykdommer | |
| BRPI0810336A2 (pt) | "método para tratar e/ou prevenir úlceras de pele em um indivíduo" | |
| NO20063430L (no) | Generelt lineaer, brusende oral fentanyl doseringsform, og metoder for administrering | |
| WO2007067946A3 (en) | Diagnosis and treatment of chronic lymphocytic leukemia (cll) | |
| SG155188A1 (en) | Pyrrole derivatives as pharmaceutical agents | |
| EA200400966A1 (ru) | Новые лекарственные формы замещенного бензимидазола и способ их применения | |
| UA88440C2 (ru) | ЛЕЧЕНИЕ ГЛОМЕРУЛОНЕФРИТА И ХРОНИЧЕСКОЙ ПОЧЕЧНОЙ НЕДОСТАТОЧНОСТИ ПРИ ПОМОЩИ ИНТЕРФЕРОНА-β | |
| ATE435663T1 (de) | Krebstherapie mit einem nukleären rezeptorliganden und einem hdac-hemmer | |
| DE60125417D1 (de) | Verminderung der nebenwirkungen der chemotherapie in krebspatienten | |
| NO20024646L (no) | Kombinasjonsterapier med vaskul¶r-skadende aktivitet | |
| DE602004022266D1 (de) | Lkarzinoms der blase | |
| MA37777B1 (fr) | Préparation pharmaceutique | |
| BR112023020219A2 (pt) | Anticorpos anti-il-2r agonistas e métodos de uso | |
| WO2020176654A8 (en) | Use of caseinolytic protease p function as a biomarker of drug response to imipridone-like agents | |
| SV2008002856A (es) | 2-amino-7, 8-dihidro-6h-pirido [4,3-d] pirimidina-5-onas | |
| NO20091628L (no) | Kombinasjonsmedikament | |
| ATE489628T1 (de) | Galk1s als modifikatoren des pten/akt-wegs | |
| TW200738255A (en) | Methods of regulating renalase (Monoamine Oxidase C) | |
| WO2022109588A3 (en) | Cancer drug sensitivity determining markers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |